Navigation Links
Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
Date:12/7/2009

M.D. added, "While SOLESTA is already available in Europe, we are confident that the publication of the study will enhance the adoption of this important treatment among the European professional community to help patients suffering from this condition."

About the Study

The Investigational Device Exemption Study was a randomized, subject and evaluator blinded, controlled, multi-center study designed to evaluate the efficacy and safety of SOLESTA for the treatment of fecal incontinence. More than 200 patients suffering from fecal incontinence were included in 13 study sites throughout the United States and Europe. Primary endpoints of the study looked at the efficacy of both groups at six months as well as evaluated the durability of response in the SOLESTA treatment group at 12 months.

About SOLESTA(TM)

SOLESTA is approved for use in Europe and Canada as an injectable treatment for fecal incontinence. SOLESTA is a biocompatible substance composed of stabilized hyaluronic acid, including dextranomer, manufactured according to Q-Med AB's patented technology, NASHA(TM). The treatment is a minimally invasive, in-office procedure. SOLESTA was developed in 2004 by Q-Med AB in Sweden. Oceana Therapeutics acquired the global rights to market and sell SOLESTA in June 2009.

About Q-Med AB

Q-Med is a medical device company that primarily develops, manufactures, markets and sells medical implants. Most of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The company today has approximately 650 co-workers in 20 countries, with approximately 400 at the company's head office and production facility in Uppsala. Q-Med had sales of 1,272 MSEK during 2008. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.

About Oceana Therapeutics, Inc.

Oceana Therapeutics was
'/>"/>

SOURCE Oceana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Pharmaceutical and biotech ... multiple products for the same indication. This can be ... want to prevent one of their brands from gaining ... According to recent research by benchmarking firm, Best Practices, ... independent brands rather than together as part of a ...
(Date:2/27/2015)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: VTAE ).  Such investors are advised ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ... and/or directors have violated Sections 10(b) and 20(a) of ... On February 27, 2015, the Company announced that its ...
(Date:2/27/2015)... Feb. 27, 2015  Following a bipartisan vote ... moved H.R. 284, the Medicare DMEPOS Competitive Bidding ... for Homecare (AAHomecare) released a statement praising the ... pass the legislation. "Today,s mark-up of ... Ways and Means Committee is a critical step ...
Breaking Medicine Technology:New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2
... has named Neogen Corporation (Nasdaq: NEOG ) to its ... ninth time in the last 11 years, and the sixth consecutive ... recognition of our company,s solid performance, and especially when it comes ... CEO. "Companies must clear a series of tough hurdles in order ...
... Life Sciences, Inc. (Nasdaq: CALP ) today ... ILMN ) for Caliper,s LabChip ® XT ... control platform. These systems are automated alternatives to traditional ... and assessment. The LabChip platforms provide Genome Analyzer and ...
Cached Medicine Technology:Neogen Again Named to Forbes' List of Best Small Companies 2Caliper Life Sciences Signs Co-Marketing Pact with Illumina to Improve Sequencing Workflows 2
(Date:3/1/2015)... (PRWEB) March 01, 2015 Theme and ... new transition pack for Final Cut Pro ... accordion style transitions to any FCPX editors project.” Said ... our users the tools needed to easily drag and ... The user gets many different controls over the parameters ...
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims to bridge youths ... towards the goal for a better future for all ... smaller groups will be held after the conference with ... Healthcare, Social and Volunteerism, Women and Youth Empowerment, to ... , Young adults aged between 18-30 years that have ...
(Date:2/28/2015)... Heart diseases are on the rise ... urban adult population and 5 percent of rural adult ... 20-30 percent of them require specialized investigation and treatment ... vascular diseases (CVD). , A division of Indian Business ... report titled “Indian Coronary Stent Market Forecast to 2019”. ...
(Date:2/28/2015)... 2015 Gerald “Solutionman” Haman surveyed over ... barriers to innovative thinking. “The #1 block was ... of tools,” reports Haman, who created the Thinkubator Innovation ... people felt that they did not have enough time ... resources to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2
... Offerings to Help Hospitals Prevent Infections, DUBLIN, ... of products and services that improve the safety ... agreement to,acquire the assets of privately held Enturia ... leading line of infection prevention,products sold under the ...
... Organizations Levy Coinsurance, Charges and Other Protocols ... ... Report from Decision Resources, WALTHAM, Mass., March ... and advisory firms for pharmaceutical and,healthcare issues, finds that ...
... Begin Today at 9:00 a.m. ET -, VALENCIA, ... today reported financial results for the fourth,quarter and year ... of 2007, total operating expenses were $79.1,million, compared to ... development (R&D) expenses increased by $7.0 million to $66.8 ...
... March 4 Crdentia Corp. (OTC Bulletin,Board: ... staffing services,today announced the appointment of Mr. ... and Chief Clinical Officer. In this newly ... regulatory compliance and accreditation, assisting in business,plan ...
... 2007 Total Revenue Increased 46.1%, Net Income Rose ... Simcere Pharmaceutical,Group (NYSE: SCR ), a leading ... and supplier of the patented anti-cancer,product Endu in ... ended December 31, 2007 and fiscal year ended ...
... , - Online Resource to Support ... the world-leading publisher of scientific, technical and,medical ... launch of,its Publishing Ethics Resource Kit (PERK),( ... Elsevier Editors, Conference in Singapore, Mark,Seeley, Senior ...
Cached Medicine News:Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 2Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 3Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 4Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 5Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 6Health News:Although Remicade and Humira Are Being Increasingly Prescribed for Crohn's Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies 2Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer 2Health News:Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer 3Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 12Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 14Health News:Elsevier Launches Publishing Ethics Resource Kit 2
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th...
... a key participant in the area of ... decade. Previous Medtronic autotransfusion systems allowed clinicians ... well as to determine requirements for a ... (PRP) for a small amount of autologous ...
... SJM Pericardial Patch with EnCap technology ... vessel reconstruction/repair and for pericardial closure. ... offers surgeons durability and flexibility, plus ... patches. Equally important in a tissue ...
... triaxial catheter design and ergonomic handle ... proprietary radiopaque Nitinol markers on the ... stent enhance visibility. Corrugated ring design ... the nested ring pattern minimizes stent ...
Medicine Products: